News
NVCN
--
0.00%
--
Neovasc Reducer Featured in Three Peer Reviewed Publications Supporting Reducer Therapy
Vancouver, Bristish Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 19, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that the Neovasc Reducer™ ("Reducer") was prominently featured in three peer...
Newsfile · 6d ago
LITE, NOV among premarket losers
ProPhase Labs (PRPH) -23% after pricing equity offering.Neovasc (NVCN) -18%.Biohaven Pharmaceutical (BHVN) -13%.Yield10 Bioscience (YTEN) -12%.Technical Communications (TCCO) -10% after receiving delisting notice from Nasdaq.InVivo Therapeutics (NVIV) -8%....
Seekingalpha · 6d ago
Neovasc drops 18% after announcing FDA rejection for Neovasc Reducer
Neovasc (NVCN) is trading ~18.3% lower in post-market hours after the company announced the receipt of a 'not-approvable' letter from the FDA regarding its PMA (premarket approval) submission for the Neovasc Reducer™.The
Seekingalpha · 01/15 22:23
Neovasc Responds to FDA Not-Approvable Letter Regarding Neovasc Reducer(TM)
Vancouver, British Columbia--(Newsfile Corp. - January 15, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has received a "not-approvable" letter from U.S. Food & Drug Administration (FDA) regarding its ...
Newsfile · 01/15 22:14
Neovasc Announces That It Responded To The FDA Not-Approvable Letter Regarding Its Neovasc Reducer
VANCOUVER and MINNEAPOLIS, Jan. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (Nasdaq, TSX: NVCN) announced today that it has received
Benzinga · 01/15 22:00
Neovasc Responds to FDA Not-Approvable Letter Regarding Neovasc Reducer
VANCOUVER and MINNEAPOLIS, Jan. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has received a “not-approvable” letter from U.S. Food & Drug Administration (FDA) regardi...
GlobeNewswire · 01/15 21:59
Neovasc Announces Participation in H.C. Wainwright BioConnect 2021 Virtual Conference
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 4, 2021) -  . (NASDAQ: NVCN) (TSX: NVCN) today announced its participation in the H.C. Wainwright BioConnect 2021 Virtual Conference, which takes place January 11-14, 2021. ...
Newsfile Corp · 01/04 21:07
Neovasc Announces Participation in H.C. Wainwright BioConnect 2021 Virtual Conference
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 4, 2021) -  Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) today announced its participation in the H.C. Wainwright BioConnect 2021 Virtual Conference, which takes place January 11-...
Newsfile · 01/04 21:05
Neovasc Highlights Publication Of Peer-Reviewed Article In EuroIntervention
REDUCER I Study Shows Improvement in Chest Pain Symptoms   VANCOUVER and MINNEAPOLIS, Dec. 17, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. ("Neovasc" or the
Benzinga · 12/17/2020 12:05
Neovasc Announces Publication of Peer-Reviewed Article in EuroIntervention
REDUCER I Study Shows Improvement in Chest Pain Symptoms
GlobeNewswire · 12/17/2020 12:00
Thinking about buying stock in Veru Inc, Neovasc, Sio Gene Therapies, Tilray, or Heat Biologics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VERU, NVCN, SIOX, TLRY, and HTBX.
PR Newswire - PRF · 12/16/2020 13:30
The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 14)
Benzinga · 12/15/2020 12:52
Neovasc Announces First Neovasc Reducer Implants In France
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 15, 2020) - Neovasc Inc. (NASDAQ:NVCN) (TSX:NVCN) ("Neovasc" or the "Company") announced today that it has
Benzinga · 12/15/2020 12:04
Neovasc Announces First Neovasc Reducer(TM) Implants in France
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 15, 2020) - (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has completed the first three Neovasc Reducer™ ("Reducer") implants in France. The implants are an important step for Neovasc as the Company continues to expand access for Reducer therapy to patients suffering from refractory angina.
Newsfile Corp · 12/15/2020 12:02
Neovasc Announces First Neovasc Reducer(TM) Implants in France
via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has completed the first three Neovasc Reducer(TM) ("Reducer") implants in France. The implants are an important step for Neovasc as the Company continues to expand access for Reducer therapy to patients suffering from refractory angina.
GlobeNewswire · 12/15/2020 12:00
Neovasc Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 14, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common shares for the 30 consecutive business days from October 30, 2020 to December 11, 2020, the Company no longer meets the minimum bid price requirement.
Newsfile Corp · 12/14/2020 23:41
Neovasc receives Nasdaq notification regarding minimum market value deficiency
Neovasc ([[NVCN]] -0.6%) received written notification from The Nasdaq Stock Market LLC, for non compliance with the minimum market value requirement.Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum
Seekingalpha · 12/11/2020 16:56
Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency
Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 10, 2020) - Neovasc, Inc. (NASDAQ:NVCN)
Benzinga · 12/10/2020 23:00
Neovasc Announces Closing of US$6.1 Million Registered Direct Offering Priced At-The-Market
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 10, 2020) -   (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has closed its previously announced registered direct offering (the "Offering") priced at-the-market under the Nasdaq Capital Market (the "Nasdaq") rules of an aggregate of 6,230,803 common shares at a price of US$0.9801 per common share. Aggregate gross proceeds to the Company were approximately US$6.1 million, before deducting placement agent's fees and estimated expenses of the Offering payable by the Company.
Newsfile Corp · 12/10/2020 21:41
The Daily Biotech Pulse: Roche & Moderna Strike COVID Testing Partnership, Rocket Pharma's Gene Therapy Readout, Breast Cancer Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 8)
Benzinga · 12/09/2020 12:23
Webull provides a variety of real-time NVCN stock news. You can receive the latest news about Neovasc through multiple platforms. This information may help you make smarter investment decisions.
About NVCN
Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.
More